GO:0017083 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0017083 describes the enzymatic transfer of L-fucose from GDP-beta-L-fucose to the 3-position of N-acetylglucosamine within a beta-D-galactosyl-(1,4)-N-acetyl-D-glucosaminyl-R acceptor, generating alpha1,3-fucosylated glycans.
• This activity is synonymous with alpha1,3-fucosyltransferase (FUT) activity and is responsible for synthesizing sialyl Lewis X and related selectin ligands on cell-surface glycoproteins and glycolipids.
• Key human genes encoding this activity include FUT3, FUT4, FUT5, FUT6, FUT7, and FUT9, which differ in tissue distribution and acceptor specificity.
• The reaction product, alpha1,3-fucosylated N-acetyllactosamine, is a minimal recognition determinant for E-, P-, and L-selectins and is critical for leukocyte extravasation and tumor metastasis.
• Dysregulated alpha1,3-fucosylation is associated with clear cell renal cell carcinoma, leukemia, and trophoblast invasion, making the enzyme a candidate biomarker and therapeutic target.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models enable precise dissection of individual FUT genes and their contributions to glycosylation-dependent phenotypes.
Description
4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase activity (GO:0017083) is a molecular function defined by the transfer of L-fucose from GDP-beta-L-fucose to the 3-hydroxyl group of N-acetylglucosamine in a beta-D-galactosyl-(1,4)-N-acetyl-D-glucosaminyl-R acceptor, yielding GDP and an alpha1,3-fucosylated product. This enzymatic step is a committed reaction in the biosynthesis of fucosylated type 2 chain glycans, including the sialyl Lewis X (sLeX) epitope, which serves as a ligand for selectins. The activity is encoded by a family of alpha1,3-fucosyltransferase genes (FUT3, FUT4, FUT5, FUT6, FUT7, FUT9) that exhibit distinct tissue expression and substrate preferences. Researchers study GO:0017083 because its products regulate cell adhesion, signaling, and immune recognition, and because altered fucosylation is a hallmark of several cancers and inflammatory conditions. Understanding this activity at the molecular level informs the development of glycoengineered cell models and targeted therapeutics.
4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase activity At A Glance
| GO ID | GO:0017083 |
|---|---|
| GO term | 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase activity |
| Ontology | molecular_function |
| Synonym | galactoside 3-fucosyltransferase activity; Lewis-negative alpha-3-fucosyltransferase activity; plasma alpha-3-fucosyltransferase activity |
| Major function | Transfer of L-fucose from GDP-beta-L-fucose to the 3-position of N-acetylglucosamine in beta-D-galactosyl-(1,4)-N-acetyl-D-glucosaminyl-R acceptors, producing alpha1,3-fucosylated glycans |
| Reaction | GDP-beta-L-fucose + beta-D-galactosyl-(1,4)-N-acetyl-D-glucosaminyl-R = GDP + 1,4-beta-D-galactosyl-(1,4)-[alpha-L-fucosyl-(1,3)]-N-acetyl-D-glucosaminyl-R |
| Cofactors | Divalent cations such as manganese are typically required for fucosyltransferase activity, though specific cofactor requirements may vary among isoenzymes |
| Subcellular location | Golgi apparatus membrane; the catalytic domain faces the lumen |
| Representative genes | FUT3, FUT4, FUT5, FUT6, FUT7, FUT9 |
What Is GO:0017083?
In simple terms, GO:0017083 is the enzyme activity that attaches a fucose sugar to another sugar (N-acetylglucosamine) that is already linked to galactose on a glycoprotein or glycolipid. The reaction uses GDP-beta-L-fucose as the donor and produces GDP plus a fucosylated product with an alpha1,3 linkage. This activity is also known as galactoside 3-fucosyltransferase, Lewis-negative alpha-3-fucosyltransferase, or plasma alpha-3-fucosyltransferase, reflecting its historical names and tissue sources.
Why Is 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase activity Important in Cell Biology?
GO:0017083 is important because the alpha1,3-fucosylated glycans it produces are key determinants of cell-cell recognition, immune cell trafficking, and cancer progression. The sialyl Lewis X epitope generated by this activity is the minimal ligand for selectins, mediating leukocyte rolling and extravasation during inflammation. In cancer, elevated alpha1,3-fucosylation correlates with metastasis and poor prognosis, as seen in clear cell renal cell carcinoma where CD15 (a fucosylated epitope) is a risk predictor and therapeutic target. Additionally, fucosylation of proteins such as MEST promotes trophoblast invasion, linking this activity to placental biology. Therefore, understanding and manipulating GO:0017083 is essential for basic glycobiology and for developing glyco-targeted diagnostics and therapeutics.
• Synthesizes sialyl Lewis X and related selectin ligands that mediate leukocyte adhesion and extravasation.
• Contributes to tumor metastasis by promoting adhesion of cancer cells to endothelium.
• Modulates receptor signaling and protein function through fucosylation, as shown for TIMP-1.
• Plays a role in trophoblast invasion and placental development via MEST fucosylation.
• Is a biomarker in clear cell renal cell carcinoma, where CD15 expression predicts risk.
• Involved in leukemia cell death pathways, with cafestol modulating fucosylation.
• Affects immune responses by regulating CD15 and IL-17RA expression.
• Provides targets for glycoengineering of therapeutic proteins and cell-based therapies.
• Enables study of glycosylation-dependent signaling in stem cell and developmental models.
• Offers opportunities for CRISPR-based functional genomics of glycosyltransferase families.
Molecular Mechanism of 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase activity
Substrate recognition and binding
In simple terms: The enzyme grabs a fucose-carrier molecule and a sugar chain that ends in galactose-N-acetylglucosamine.
The enzyme binds GDP-beta-L-fucose and an acceptor oligosaccharide terminating in beta-D-galactosyl-(1,4)-N-acetyl-D-glucosaminyl-R. The acceptor is typically presented on N-glycans, O-glycans, or glycolipids. Specificity for the 3-position of N-acetylglucosamine is determined by the enzyme's active site architecture, which orients the acceptor for in-line nucleophilic attack.
Catalytic transfer of fucose
In simple terms: The enzyme snips off fucose from GDP and attaches it to the sugar chain.
The catalytic mechanism involves a glycosyl transfer reaction where the anomeric carbon of fucose is attacked by the 3-hydroxyl group of N-acetylglucosamine, resulting in an alpha1,3 linkage and release of GDP. This reaction is thought to proceed via an oxocarbenium ion-like transition state, common to retaining glycosyltransferases.
Cofactor requirements and metal ions
In simple terms: Some versions of the enzyme need a metal helper to work.
Many alpha1,3-fucosyltransferases require divalent metal ions such as manganese for optimal activity, although the exact dependence varies among isoenzymes. The metal ion likely stabilizes the GDP-fucose donor and the transition state.
Regulation by gene expression and post-translational modifications
In simple terms: Cells control how much enzyme is made and how active it is.
The activity is regulated at the transcriptional level by tissue-specific promoters and transcription factors such as AP1, which mediates uPA/uPAR-induced FUT4 expression in trophoblasts. Post-translational modifications and Golgi retention signals also influence enzyme localization and activity.
Product function and downstream effects
In simple terms: The fucose tag changes how cells stick and talk to each other.
The alpha1,3-fucosylated product, such as sialyl Lewis X, serves as a ligand for selectins, mediating cell adhesion. It also modulates receptor signaling and protein stability, as seen with TIMP-1 where outer-arm fucose reduces its activity. These downstream effects link the enzymatic activity to inflammation, cancer, and development.
Key Genes Involved in GO:0017083 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase activity
The following genes encode enzymes with 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase activity or are directly involved in its regulation and downstream biology.
| Gene | Major Role | Research Relevance |
|---|---|---|
| FUT3 | Encodes Lewis blood group alpha1,3/4-fucosyltransferase; synthesizes sialyl Lewis X and Lewis A | Polymorphisms affect Lewis antigen status and cancer susceptibility |
| FUT4 | Myeloid-specific alpha1,3-fucosyltransferase; synthesizes CD15 and sialyl Lewis X | Regulated by AP1; involved in trophoblast invasion and leukemia |
| FUT5 | Alpha1,3-fucosyltransferase expressed in various tissues | Less studied; potential redundancy with FUT3/6 |
| FUT6 | Plasma alpha1,3-fucosyltransferase; synthesizes sialyl Lewis X | Associated with plasma fucosyltransferase activity and cancer |
| FUT7 | Leukocyte-specific alpha1,3-fucosyltransferase; essential for selectin ligand synthesis | Critical for leukocyte trafficking and inflammation |
| FUT9 | Neural and embryonic alpha1,3-fucosyltransferase; synthesizes CD15 and Lewis X | Roles in brain development and stem cells |
| MEST | Alpha1,3-fucosylation target; promotes trophoblast invasion | Fucosylation activates translation initiation |
| TIMP1 | Glycoprotein substrate; outer-arm fucose reduces activity | Fucosylation modulates protease inhibition |
| CD15 | Fucosylated epitope (Lewis X) on glycoproteins | Biomarker in renal cell carcinoma and immune regulation |
| IL17RA | Cytokine receptor; expression affected by CD15 status | Linked to avelumab response and STAT3 signaling |
| STAT3 | Transcription factor; reduced by avelumab, affecting CD15 | Connects fucosylation to immune signaling |
| AP1 | Transcription factor mediating FUT4 expression | uPA/uPAR-induced FUT4 in trophoblasts |
| uPA | Plasminogen activator; induces FUT4 via AP1 | Regulates trophoblast invasion |
| uPAR | uPA receptor; upstream of FUT4 induction | Same pathway as uPA |
| GDP-fucose transporter | Transports GDP-fucose into Golgi for fucosylation | Essential for substrate supply |
| GMPPA | Golgi membrane protein involved in fucosylation | Potential regulator |
| SLC35C1 | GDP-fucose transporter; mutations cause leukocyte adhesion deficiency II | Defects in fucosylation |
| FUT8 | Alpha1,6-fucosyltransferase (distinct from GO:0017083) | Often studied alongside alpha1,3-FUTs |
How Is 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase activity Regulated?
The activity of 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase is regulated at multiple levels. Transcriptionally, FUT4 is induced by AP1 downstream of uPA/uPAR signaling in trophoblasts. In cancer, STAT3 signaling modulates CD15 expression, and avelumab reduces STAT3 with effects on IL-17RA and CD15. Post-translational regulation includes Golgi retention and potential phosphorylation. Substrate availability, particularly GDP-fucose levels controlled by the GDP-fucose transporter SLC35C1, also influences activity. Additionally, fucosylation of specific substrates like MEST can activate translation initiation, creating feedback loops.
4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FUT4 | Trophoblast invasion, leukemia | Knockout in JEG-3 or HL-60 cells |
| CD15 | Clear cell renal cell carcinoma | Overexpression in 786-O cells |
| MEST | Trophoblast invasion | Point mutation of fucosylation sites in HTR-8/SVneo cells |
| STAT3 | Immune response, cancer | Knockout in immune cells treated with avelumab |
| TIMP1 | Protease inhibition | Knock-in of fucosylation site mutants in HEK293 |
Cancer and metastasis
Elevated alpha1,3-fucosylation is associated with tumor progression and metastasis. In clear cell renal cell carcinoma, CD15 (a product of this activity) is a risk predictor and a novel target. FUT4 expression, mediated by AP1, promotes trophoblast invasion, a process co-opted in cancer invasion. Cafestol induces leukemia cell death, potentially by modulating fucosylation pathways.
Inflammation and immune disorders
Sialyl Lewis X synthesized by this activity is the ligand for selectins, mediating leukocyte extravasation. Altered fucosylation affects immune responses; avelumab treatment reduces STAT3 and impacts CD15 and IL-17RA expression, linking fucosylation to immunotherapy response.
Placental development and trophoblast biology
Alpha1,3-fucosylation of MEST promotes invasion potential of cytotrophoblast cells by activating translation initiation, highlighting a role in placental development. FUT4 induction by uPA/uPAR also contributes to trophoblast invasion.
From 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does FUT4 knockout reduce sialyl Lewis X and invasion? | FUT4 knockout in JEG-3 trophoblast cells |
| Does fucosylation of MEST at specific sites affect translation? | Point mutation of MEST fucosylation sites in HTR-8/SVneo |
| Can CD15 overexpression drive renal carcinoma aggressiveness? | CD15 knock-in in 786-O cells |
| Does STAT3 knockout mimic avelumab effects on CD15? | STAT3 knockout in immune cell lines |
| Does TIMP1 fucosylation alter its activity? | Knock-in of fucosylation-deficient TIMP1 in HEK293 |
| Can FUT7 overexpression enhance selectin ligand synthesis? | FUT7 overexpression in CHO cells |
How to Study the 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Mass spectrometry | Glycan composition and fucosylation sites | Characterizing products of GO:0017083 |
| Flow cytometry | Cell-surface fucosylated epitopes (e.g., CD15, sLeX) | Screening knockout clones |
| Lectins (UEA-I) | Alpha1,3-fucose residues | Detecting fucosylation changes |
| Enzymatic assay | Fucosyltransferase activity | Measuring specific activity in lysates |
| CRISPR screen | Genes affecting fucosylation | Identifying regulators |
| Western blot | Protein expression of FUTs | Validating knockout/overexpression |
| qRT-PCR | mRNA levels of FUT genes | Assessing transcriptional regulation |
| Immunohistochemistry | Tissue expression of fucosylated antigens | Clinical correlation in cancer |
Glycan analysis by mass spectrometry
Mass spectrometry-based glycomics and glycoproteomics can identify and quantify alpha1,3-fucosylated structures on glycoproteins and glycolipids. This method reveals the specific products of GO:0017083 and can be used to assess changes upon gene editing.
Flow cytometry with fucose-specific lectins
Lectins such as UEA-I or anti-sialyl Lewis X antibodies can detect cell-surface fucosylation by flow cytometry. This approach is useful for screening CRISPR knockout clones for loss of alpha1,3-fucosylation.
Enzymatic activity assays
In vitro fucosyltransferase assays using fluorescent or radioactive GDP-fucose and acceptor substrates measure the specific activity of FUT enzymes. These assays can be performed on cell lysates or recombinant enzymes.
CRISPR screening and functional genomics
Genome-wide CRISPR knockout screens can identify genes required for alpha1,3-fucosylation and its downstream functions, such as selectin binding or immune recognition. This method links genotype to glycosylation phenotype.
How CRISPR Can Be Used to Study GO:0017083 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase activity
Knockout
CRISPR knockout of individual FUT genes (e.g., FUT4, FUT7) eliminates specific alpha1,3-fucosyltransferase activity, enabling study of their unique contributions to glycan synthesis and cell behavior. For example, FUT4 knockout in trophoblast cells reduces invasion.
Point Mutation
Introducing point mutations in the catalytic domain of FUT genes can abolish enzymatic activity without affecting protein expression, providing a clean way to separate catalytic function from other roles. Similarly, point mutations in acceptor sites (e.g., MEST) can prevent fucosylation and reveal its impact on protein function.
Knock-in
Knock-in of epitope tags or fluorescent reporters into endogenous FUT loci allows real-time tracking of enzyme localization and dynamics. Knock-in of fucosylation site mutants into substrate proteins (e.g., TIMP1) can test the functional consequences of specific glycosylation events.
Overexpression
Overexpression of FUT genes in cell lines (e.g., CHO, HEK293) increases alpha1,3-fucosylation and can be used to produce glycoengineered proteins or to study gain-of-function phenotypes, such as enhanced selectin binding.
How EDITGENE Supports 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase activity Research
Researchers studying 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in glycosylation-dependent phenotypes. EDITGENE provides a comprehensive suite of CRISPR services to generate precisely engineered cell models for functional validation.
Contact EDITGENE today to design your custom CRISPR model for 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase activity research.
Frequently Asked Questions About 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase activity
What is 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase activity?
It is an enzyme activity (GO:0017083) that transfers fucose from GDP-beta-L-fucose to the 3-position of N-acetylglucosamine in a beta-D-galactosyl-(1,4)-N-acetyl-D-glucosaminyl-R acceptor, producing an alpha1,3-fucosylated glycan.
What genes are involved in 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase activity?
The main genes are FUT3, FUT4, FUT5, FUT6, FUT7, and FUT9, which encode alpha1,3-fucosyltransferases with different tissue distributions.
What is the reaction catalyzed by GO:0017083?
The reaction is: GDP-beta-L-fucose + beta-D-galactosyl-(1,4)-N-acetyl-D-glucosaminyl-R = GDP + 1,4-beta-D-galactosyl-(1,4)-[alpha-L-fucosyl-(1,3)]-N-acetyl-D-glucosaminyl-R.
What diseases are associated with alpha1,3-fucosyltransferase activity?
It is linked to cancer (e.g., clear cell renal cell carcinoma), inflammation, and placental development.
How can I study 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase activity?
You can use enzymatic assays, mass spectrometry, flow cytometry with lectins, and CRISPR knockout models to study this activity.
What is the role of FUT4 in trophoblast invasion?
FUT4, induced by AP1 downstream of uPA/uPAR, promotes trophoblast invasion by synthesizing fucosylated glycans.
Is CD15 a product of this enzyme activity?
Yes, CD15 (Lewis X) is a fucosylated epitope synthesized by alpha1,3-fucosyltransferases, including FUT4 and FUT9.
How does fucosylation affect TIMP-1?
Outer-arm fucose residues on TIMP-1 N-glycans reduce its activity as a protease inhibitor.
What is the connection between alpha1,3-fucosylation and MEST?
Alpha1,3-fucosylation of MEST promotes invasion of cytotrophoblast cells by activating translation initiation.
Can CRISPR be used to knockout FUT genes?
Yes, CRISPR knockout of FUT genes is a powerful approach to eliminate specific alpha1,3-fucosyltransferase activity and study its functions.
Conclusion
GO:0017083, 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase activity, is a central enzymatic function in the biosynthesis of alpha1,3-fucosylated glycans that regulate cell adhesion, signaling, and immune recognition. Its products, such as sialyl Lewis X and CD15, are implicated in cancer progression, inflammation, and placental biology. Understanding the molecular mechanism and regulation of this activity provides opportunities for therapeutic intervention and glycoengineering. CRISPR-based models are indispensable for dissecting the roles of individual FUT genes and their substrates, and EDITGENE offers comprehensive services to support such research.
References
- 1. Vora P et al.. 2015. Culture and Isolation of Brain Tumor Initiating Cells.. Curr Protoc Stem Cell Biol 34:3.3.1-3.3.13 PMID: 26237571
- 2. Szlasa WK et al.. 2024. Avelumab reduces STAT3 expression with effects on IL-17RA and CD15.. Dent Med Probl 61(5):713-720 PMID: 39480959
- 3. Lima CS et al.. 2017. Cafestol, a diterpene molecule found in coffee, induces leukemia cell death.. Biomed Pharmacother 92:1045-1054 PMID: 28618649
- 4. Zheng Q et al.. 2018. AP1 mediates uPA/uPAR induced FUT4 expression and trophoblast invasion.. J Cell Biochem 119(8):6442-6451 PMID: 29278651
- 5. Kim HIe et al.. 2013. The presence of outer arm fucose residues on the N-glycans of tissue inhibitor of metalloproteinases-1 reduces its activity.. J Proteome Res 12(8):3547-60 PMID: 23815085
- 7. Stenzel PJ et al.. 2024. CD15 Is a Risk Predictor and a Novel Target in Clear Cell Renal Cell Carcinoma.. Pathobiology 91(3):219-229 PMID: 37963432
- 8. Wang H et al.. 2023. α1,3-fucosylation of MEST promotes invasion potential of cytotrophoblast cells by activating translation initiation.. Cell Death Dis 14(10):651 PMID: 37798282
